| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLCA1 |
| Uniprot No | A8K7I4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 677-776aa |
| 氨基酸序列 | ALGGVNAARRRVIPQQSGALYIPGWIENDEIQWNPPRPEINKDDVQHKQV CFSRTSSGGSFVASDVPNAPIPDLFPPGQITDLKAEIHGGSLINLTWTAP |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLCA1重组蛋白的3篇参考文献概览：
1. **文献名称**: *"CLCA1 modulates airway mucus production through MAPK/ERK signaling in asthma"*
**作者**: Patel, S. et al. (2018)
**摘要**: 研究通过表达重组CLCA1蛋白，发现其激活MAPK/ERK通路，促进气道上皮细胞黏蛋白MUC5AC分泌，提示CLCA1在哮喘气道黏液高分泌中的关键作用。
2. **文献名称**: *"Recombinant CLCA1 regulates chloride transport in vitro and airway hyperresponsiveness in murine models"*
**作者**: Zhang, L. et al. (2020)
**摘要**: 利用重组CLCA1蛋白进行体外跨膜氯离子流测定，证实其增强上皮细胞氯离子转运能力;动物实验表明CLCA1重组蛋白加剧卵清蛋白诱导的小鼠气道高反应性。
3. **文献名称**: *"Structural and functional characterization of the CLCA1 N-terminal domain expressed in HEK293 cells"*
**作者**: Garcia, G. et al. (2017)
**摘要**: 通过HEK293系统表达CLCA1重组蛋白N端结构域，结合X射线晶体学解析其三维结构，揭示其与钙离子结合的分子机制，为靶向药物设计提供依据。
**备注**：以上文献为示例，实际引用时需核实真实来源及发表信息。建议通过PubMed或Web of Science以关键词“CLCA1 recombinant protein”检索近期实验性研究论文。
CLCA1 (Calcium-Activated Chloride Channel Regulator 1) is a member of the CLCA protein family, which plays roles in modulating calcium-activated chloride channel activity, though its exact mechanistic function remains debated. Initially misclassified as a chloride channel itself, CLCA1 is now recognized as a secreted self-cleaving metalloprotease that regulates downstream ion channels or signaling pathways. It is predominantly expressed in epithelial tissues, including the respiratory and intestinal tracts, and is implicated in mucus production, inflammation, and tissue remodeling.
The CLCA1 recombinant protein is engineered to mimic the functional extracellular domain of the native protein, typically produced using mammalian expression systems (e.g., HEK293 cells) to ensure proper post-translational modifications. It consists of multiple domains: an N-terminal signal peptide, a metalloprotease-like domain responsible for auto-proteolytic cleavage, and a C-terminal lectin-like domain that may mediate interactions with cell surfaces or extracellular matrix components.
Research highlights its dual role in health and disease. In normal physiology, CLCA1 supports mucosal hydration and antimicrobial defense. However, its overexpression is linked to pathologies such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis, where it exacerbates mucus hypersecretion and airway obstruction. CLCA1 also interacts with cytokines (e.g., IL-13) and signaling pathways (e.g., MAPK/ERK), positioning it as a potential therapeutic target.
Recombinant CLCA1 protein is widely used in vitro to study chloride channel regulation, epithelial barrier function, and inflammatory responses. It also aids in developing antibodies or inhibitors for preclinical studies. Despite progress, controversies persist regarding its direct vs. indirect effects on ion channels, driving ongoing structural and functional investigations to clarify its molecular mechanisms.
×
